NEW YORK (GenomeWeb News) – Stratagene said today that it has formed a joint development and license agreement with Rosetta Inpharmatics to create automated solution for the isolation of nucleic acids from clinical samples. Under the deal, the companies will jointly develop an instrument and a single-use consumable, which will be manufactured Stratagene for sale to its customers engaged in pharmacogenomics. Additional terms of the agreement were not disclosed.